Lidoderm (lidocaine 5% patch)

LIDODERM (lidocaine patch 5%) – topical patch formulation of lidocaine commonly used to treat neuropathic pain. Lidocaine is an amide-type local anesthetic agent and is suggested to stabilize neuronal membranes by inhibiting the ionic fluxes required for the initiation and conduction of impulses. The penetration of lidocaine into intact skin after application of LIDODERM is sufficient to produce an analgesic effect, but less than the amount necessary to produce a complete sensory block.

FDA approved uses: Lidoderm is indicated for relief of pain associated with post-herpetic neuralgia.

Available dosage forms: Topical patch containing 5% lidocaine.

Usual dosage: Apply LIDODERM to intact skin to cover the most painful area. Apply up to three patches, only once for up to 12 hours within a 24-hour period. Patches may be cut into smaller sizes with scissors prior to removal of the release liner.

Contraindications: Lidoderm (lidocaine patch 5% hydrochloride) is contraindicated in patients with known hypersensitivity to local anesthetics of the amide type or to any excipients used in the formulation.

Special warnings: Accidental Exposure in Children – Even a used LIDODERM patch contains a large amount of lidocaine (at least 665 mg). The potential exists for a small child or a pet to suffer serious adverse effects from chewing or ingesting a new or used LIDODERM patch, although the risk with this formulation has not been evaluated. It is important for patients to store and dispose of LIDODERM out of the reach of children, pets and others.

Adverse reactions (side effects) of these medications: The most common side effects of Lidoderm seen in clinical trials were application site reactions. Other adverse events reported include Asthenia, confusion, disorientation, dizziness, anaphylaxis, headache, hyperesthesia, hypoesthesia, lightheadedness, metallic taste, nausea, nervousness, pain exacerbated, paresthesia, somnolence, taste alteration, vomiting, visual disturbances such as blurred vision, flushing, tinnitus, and tremor.

Common drug interactions: Antiarrhythmic Drugs – LIDODERM should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics – When LIDODERM is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.

Special instructions for patients: Use this medication exactly as directed by physician. Hands should be washed after the handling of LIDODERM, and eye contact with LIDODERM should be avoided. Do not store patch outside the sealed envelope. Apply immediately after removal from the protective envelope. Fold used patches so that the adhesive side sticks to itself and safely discard used patches or pieces of cut patches where children and pets cannot get to them. LIDODERM should be kept out of the reach of children.

Full prescribing information may be found at the manufacturer‘s official website Lidoderm.com or at the U.S. Food and Drug Administration’s website at Lidoderm Info at Drugs@FDA

Tags: , , , ,

Comments are closed.